Clinical development of cancer therapeutics that target metabolism

QJM: An International Journal of Medicine

Volumn 109, Issue 6, 2016, Pages 367-372

  Clem, B F ^a   O'Neal, J ^b   Klarer, A C ^a,c   Telang, S ^a,c   Chesney, J ^a,c  

^a University of Louisville School of Medicine   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3 PYRIDINYL) 1 (4 PYRIDINYL) 2 PROPEN 1 ONE; 6 PHOSPHOFRUCTO 2 KINASE; 6 PHOSPHOFRUCTOKINASE; ADENOSINE TRIPHOSPHATE; AG 120; ANTINEOPLASTIC AGENT; AZD 3965; BIS 2 (5 PHENYLACETAMIDO 1,2,4 THIADIAZOL 2 YL)ETHYL SULFIDE 3; CARBOPLATIN; CB 839; CPI 613; DEOXYGLUCOSE; DICHLOROACETIC ACID; DOCETAXEL; ENASIDENIB; FRUCTOSE 2,6 BISPHOSPHATASE 3; GLUTAMINASE; HEXOKINASE; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE INHIBITOR; ISOSORBIDE; LACTATE DEHYDROGENASE; MONOCARBOXYLATE TRANSPORTER 1; PFK 158; UNCLASSIFIED DRUG; TUMOR MARKER;

ACUTE MYELOBLASTIC LEUKEMIA; ADVANCED CANCER; CANCER INHIBITION; CANCER PATIENT; CANCER THERAPY; ENZYME INHIBITION; HEMATOLOGIC MALIGNANCY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRIPLE NEGATIVE BREAST CANCER; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG DESIGN; DRUG EFFECTS; ENERGY METABOLISM; ENZYMOLOGY; GENE EXPRESSION REGULATION; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; OXIDATIVE PHOSPHORYLATION; TRENDS; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DRUG DESIGN; ENERGY METABOLISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; OXIDATIVE PHOSPHORYLATION; TUMOR MICROENVIRONMENT;

EID: 84978984470     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcv181     Document Type: Review

References (39)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74.
2. Castell F, Cook GJ. Quantitative techniques in 18FDG PET scanning in oncology. Br J Cancer 2008; 98:1597-601.
3. Imbert-Fernandez Y, Clem BF, O'Neal J, Kerr DA, Spaulding R, Lanceta L, et al. Estradiol stimulates glucose metabolism via 6-phosphofructo-2-kinase (PFKFB3). J Biol Chem 2014; 289:9440-8.
4. McArthur GA, Puzanov I, Amaravadi R, Ribas A, Chapman P, Kim KB, et al. Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. J Clin Oncol 2012; 30:1628-34.
5. Clem BF, Chesney J. Regulation of metabolism by Rb. Clin Cancer Res 2012; 18:4
6. Hernandez-Davies JE, Tran TQ, Reid MA, Rosales KR, Lowman XH, Pan M, et al. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence. J Transl Med 2015; 13:210
7. Masui K, Tanaka K, Ikegami S, Villa GR, Yang H, Yong WH, et al. Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. Proc Natl Acad Sci USA 2015; 112:9406-11.
8. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. Hypoxiainducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 2007; 27:7381-93.
9. Landau BR, Laszlo J, Stengle J, Burk D. Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D-glucose. J Natl Cancer Inst 1958; 21:485-94.
10. Stein M, Lin H, Jeyamohan C, Dvorzhinski D, Gounder M, Bray K, et al. Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate 2010; 70:1388-94.
11. Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, et al. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2013; 71:523-30.
12. Yalcin A, Clem BF, Imbert-Fernandez Y, Ozcan SC, Peker S, O'Neal J, et al. 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27. Cell Death Dis 2014; 5:e1337
13. Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A, et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther 2008; 7:110-20.
14. Clem BF, O'Neal J, Tapolsky G, Clem AL, Imbert-Fernandez Y, Kerr DA. 2nd, et al. Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. Mol Cancer Ther 2013; 12:1461-70.
15. Xie H, Valera VA, Merino MJ, Amato AM, Signoretti S, Linehan WM, et al. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther 2009; 8:626-35.
16. Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 2003; 46:4259-64.
17. Zhao MG Y, Lin H, Harris Addo K, Taber Levinson K, LaRosiliere M, Goodin S, et al. Phase I study of at-101 (R-(-)-gossypol) in combination with paclitaxel (P) and carboplatin (C) in solid tumors including castrate-resistant prostate cancer (CRPC). J Clin Oncol 2011; 29: Abstract 169.
18. Sacco A, Nor J, Belile E, Sukari A, Chepeha D, Bradford C, et al. Phase 2 trial of AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head-and-neck squamous cell carcinoma (HNSCC). Int J Rad Oncol 2014; 88: Abstract 199.
19. Fiveash JB, Chowdhary SA, Peereboom D, Mikkelsen T, Nabors LB, Lesser GJ, et al. NABTT-0702: A phase II study of R-(-)-gossypol (AT-101) in recurrent glioblastoma multiforme (GBM). J Clin Oncol 2009; 27: Abstract 2010.
20. Peppicelli S, Bianchini F, Calorini L. Extracellular acidity, a "reappreciated" trait of tumor environment driving malignancy: perspectives in diagnosis and therapy. Cancer Metastasis Rev 2014; 33:823-32.
21. Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest 2013; 123:3685-92.
22. Bola BM, Chadwick AL, Michopoulos F, Blount KG, Telfer BA, Williams KJ, et al. Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport. Mol Cancer Ther 2014; 13:2805-16.
23. Le Floch R, Chiche J, Marchiq I, Naiken T, Ilc K, Murray CM, et al. CD147 subunit of lactate/H+symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc Natl Acad Sci U S A 2011; 108:16663-8.
24. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 2010; 35:427-33.
25. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009; 458:762-5.
26. Reynolds MR, Lane AN, Robertson B, Kemp S, Liu Y, Hill BG, et al. Control of glutamine metabolism by the tumor suppressor Rb. Oncogene 2014; 33:556-66.
27. Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J, et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 2012; 15:110-21.
28. Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther 2014; 13:890-901.
29. Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov 2013; 3:730-41.
30. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013; 340:626-30.
31. Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010; 18:207-19.
32. de Botton S. Targeting isocitrate dehydrogenase-1 (IDH1) and IDH2 mutations. Clinical results in advanced hematologic malignancies. Ann Oncol 2015; 26: Abstract O11.3.
33. Zachar Z, Marecek J, Maturo C, Gupta S, Stuart SD, Howell K, et al. Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. J Mol Med (Berl) 2011; 89:1137-48.
34. Retter AS. Translational assessment of the efficacy of CPI-613 against pancreatic cancer in animal models versus patients with stage IV disease. J Clin Oncol 2012; 30:Abstract 3075.
35. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, et al. A mitochondria-K+channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007; 11:37-51.
36. Robey IF, Martin NK. Bicarbonate and dichloroacetate: evaluating pH altering therapies in a mouse model for metastatic breast cancer. BMC Cancer 2011; 11:235
37. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Trans Med 2010; 2:31ra4
38. Dunbar EM, Coats BS, Shroads AL, Langaee T, Lew A, Forder JR, et al. Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors. Invest New Drugs 2014; 32:452-64.
39. Powell SF, Spanos WC, Black LJ, Ellison C, Miskimins WK, Puumala SE, et al. Phase II study of dichloroacetate (DCA) in combination with chemoradiation (CRT) for unresected, locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). J Clin Oncol 2015; 33: Abstract e17089.